cyno fall short franchis healthi
report sale beat consensu driven stellar breast
sale strong diagnost result distract posit
headlin cyno aesthet miss due mainli voluntari
tempsur vitalia suspens couldnt break streak
neg cyno news quarter manag point momentum
quarter fda impact cautiou lower
cyno forecast go forward separ allevi worri
contract two major lab custom announc sign multi-year
deal one multi-year extens expect week
remov overhang may help share move higher thursday
metric nitpick report gross margin
weak guidanc set consensu overal saw
decent report believ expect achiev
frustratingli familiar though manag note cyno
perform well start fda market-rel
issu hesit turnaround ad back
sale exclud impact tempsur vitalia suspens
still repres signific sequenti step-down reduc
aesthet forecast
bright spot breast health busi continu gain steam
bolster system brevera abil offer custom
product tuck-in acquisit help popular
panther push molecular diagnost revenu surgic sale
grew low singl digit salesforc recoveri start stick
look ahead holx divis expect
grow low-to-mid-singl digit breast health revenue project
increas mid-singl digit rate
valuat rate buy pt base
month adj ep estim risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
fiscal fourth quarter report total revenu
beat consensu estim btig consensu
out-performance came strong result breast health
diagnost divis off-set medic aesthet sale well
 gross margin bp lighter model sg
 spend percentag revenu slightli lower expect
bp bp respect result oper margin bp
forecast share count fiscal quarter lower wed
model thank part share repurchas adj ep one
penni estim
actualsbtig estimate variancebreast sale sale cytolog perinat molecular diagnost blood screen surgic sale novasur myosur sale sale revenu market admin incom incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
make sever adjust forecast
reflect busi trend manag commentari go forward
increas sale outlook breast health diagnost divis
reduc estim gyn surgic medic aesthet tweak
forecast skelet health sale well forecast
revenu near top end guidanc rang
forecast revenu top end rang
 reduc share count guidanc model lower gross
margin also revis forecast
adjust guidanc model adj ep
gaap ep midpoint rang project
adj ep ep top end guidanc rang
rate buy pt base
month adjust ep estim use multipl comp group
reflect compani slightli lower revenu growth investor sentiment
take time turn risk rate price target includ
cyno result adopt chang reimburs diagnost price
slowdown novasur competit success integr
cyno
revenu incom btig estim compani filingsnewold changentm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
